{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:26:10Z","timestamp":1791919570005,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd003562","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2004,10,18]],"date-time":"2004-10-18T00:00:00Z","timestamp":1098057600000}}],"reference-count":56,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003562.pub2","type":"journal-article","created":{"date-parts":[[2004,10,14]],"date-time":"2004-10-14T13:00:59Z","timestamp":1097758859000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phosphodiesterase 5 inhibitors for pulmonary hypertension"],"prefix":"10.1002","volume":"2019","author":[{"given":"Parthipan","family":"Kanthapillai","sequence":"first","affiliation":[{"name":"Luton and Dunstable NHS Trust; Lewsey Road Luton Bedfordshire UK LU4 0DZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Haydn","family":"Walters","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Tasmania; NHMRC Centre of Research Excellence for Chronic Respiratory Disease; Hobart Tasmania Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,18]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD003562.pub2-BIB0001|cit1","first-page":"55","article-title":"The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension","volume":"55","author":"Bharani","year":"2003","journal-title":"Indian Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD003562.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-136-7-200204020-00008","article-title":"Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension","volume":"136","author":"Ghofrani","year":"2002","journal-title":"Annals of Internal Medicine"},{"issue":"9337","key":"10.1002\/14651858.CD003562.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","article-title":"Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial","volume":"360","author":"Ghofrani","year":"2002","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD003562.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension","volume":"43","author":"Sastry","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"issue":"7158","key":"10.1002\/14651858.CD003562.pub2-BIB0005|cit5","first-page":"112","article-title":"Sildenafil shows some promise for the treatment of pulmonary hypertension","volume":"267","author":"Anonymous","year":"2001","journal-title":"Pharmaceutical Journal"},{"issue":"1","key":"10.1002\/14651858.CD003562.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0163-7258(00)00104-2","article-title":"Pharmacologic therapy of persistent pulmonary hypertension of the newborn","volume":"89","author":"Anonymous","year":"2001","journal-title":"Pharmacology & Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD003562.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0272-5231(05)70290-2","article-title":"New and experimental therapies for pulmonary hypertension","volume":"22","author":"Channick","year":"2001","journal-title":"Clinics in Chest Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003562.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2003.12.023","article-title":"Efficacy and optimal dose of sildenafil in primary pulmonary hypertension","volume":"99","author":"Chockalingam","year":"2005","journal-title":"International Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD003562.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0003-4975(89)90785-6","article-title":"Amrinone versus conventional therapy in pulmonary hypertensive patients awaiting cardiac transplantation","volume":"48","author":"Deeb","year":"1989","journal-title":"Annals of Thoracic Surgery"},{"issue":"9337","key":"10.1002\/14651858.CD003562.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(02)11067-1","article-title":"Pulmonary hypertension and the search for the selective pulmonary vasodilator","volume":"360","author":"Dweik","year":"2002","journal-title":"The Lancet"},{"issue":"5","key":"10.1002\/14651858.CD003562.pub2-BIB0011|cit11","first-page":"291","article-title":"Sildenafil in pulmonary hypertension","volume":"57","author":"Ewert","year":"2003","journal-title":"Pneumologie"},{"issue":"1","key":"10.1002\/14651858.CD003562.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vph.2005.03.003","article-title":"The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: Demonstration of a ceiling effect","volume":"43","author":"Frost","year":"2005","journal-title":"Vascular Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD003562.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0735-1097(03)00555-2","article-title":"Oral sildenafil as long-term adjunct therapy to inhaled Iloprost in severe pulmonary arterial hypertension","volume":"42","author":"Ghofrani","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD003562.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Ghofrani HA Reichenberger F Kohstall MG Mrosek E Seeger T Schermuly RT Sildenafil reduces hypoxia-induced pulmonary hypertension and increases exercise capacity during oxygen deprivation at a low altitude and at Mount Everest base camp: a randomized placebo controlled study American Thoracic Society 100th International Conference 2004 A56 Poster B3","DOI":"10.7326\/0003-4819-141-3-200408030-00005"},{"issue":"9","key":"10.1002\/14651858.CD003562.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1164\/rccm.200110-028PP","article-title":"New treatments for pulmonary arterial hypertension","volume":"165","author":"Hoeper","year":"2002","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"24","key":"10.1002\/14651858.CD003562.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1161\/CIRCULATIONAHA.104.473371","article-title":"Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: Twelve-month clinical trial of a single-drug, open-label, pilot study","volume":"111","author":"Humpl","year":"2005","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD003562.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.fjc.0000155386.49103.ce","article-title":"Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension","volume":"45","author":"Ikeda","year":"2005","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD003562.pub2-BIB0018|cit18","first-page":"404","article-title":"Chronic oral sildenafil therapy in severe pulmonary artery hypertension","volume":"54","author":"Kothari","year":"2002","journal-title":"Indian Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD003562.pub2-BIB0019|cit19","first-page":"7","article-title":"Acute hemodynamic response to vasodilators in primary pulmonary hypertension","volume":"42","author":"Kulkarni","year":"1996","journal-title":"Journal of Postgraduate Medicine"},{"issue":"6","key":"10.1002\/14651858.CD003562.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0002-9149(02)02586-9","article-title":"Effect of Sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension","volume":"90","author":"Lepore","year":"2002","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD003562.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2141.2005.05625.x","article-title":"Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension","volume":"130","author":"Machado","year":"2005","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD003562.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0167-5273(89)90272-6","article-title":"Long-term clinical results after vasodilator evaluation in patients with primary (unexplained) and secondary precapillary pulmonary hypertension: acute hemodynamic comparisons and long-term survival","volume":"22","author":"McKay","year":"1989","journal-title":"International Journal of Cardiology"},{"issue":"20","key":"10.1002\/14651858.CD003562.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1161\/01.CIR.0000016641.12984.DC","article-title":"Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide","volume":"105","author":"Michelakis","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD003562.pub2-BIB0024|cit24","unstructured":"Richalet JP Gratadour P Pham I Robach P Joncquiert-Latarjet A Sildenafil inhibits the altitude-induced pulmonary hypertension. A double-blind placebo-controlled study American Thoracic Society 100th International Conference 2004 A88"},{"issue":"3","key":"10.1002\/14651858.CD003562.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1164\/rccm.200406-804OC","article-title":"Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension","volume":"171","author":"Richalet","year":"2005","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003562.pub2-BIB0026|cit26","first-page":"1108","article-title":"Inhaled nitric oxide versus intravenous vasodilators in severe pulmonary hypertension after cardiac surgery","volume":"89","author":"Schmid","year":"1999","journal-title":"Anesthesia & Analgesia"},{"issue":"11","key":"10.1002\/14651858.CD003562.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/hc3601.096826","article-title":"Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension","volume":"104","author":"Wilkens","year":"2001","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD003562.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study","volume":"171","author":"Wilkins","year":"2005","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003562.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/hc2901.093117","article-title":"Sildenafil inhibits hypoxia-induced pulmonary hypertension","volume":"104","author":"Zhao","year":"2001","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD003562.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/thx.2005.041954","article-title":"Phosphodiesterase type 5 and high altitude pulmonary hypertension","volume":"60","author":"Aldashev","year":"2005","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD003562.pub2-BIB0031|cit31","unstructured":"Badesch D Burgess G Parpia T Torbicki A Sildenafil citrate in patients with pulmonary arterial hypertension (PAH) results of a multicenter multinational randomized double-blind placebo controlled trial by WHO functional class (FC) American Thoracic Society 2005 International Conference; May 20-25; San Diego, California 2005 A57; Poster: K39"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD003562.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"615s","DOI":"10.1378\/chest.128.6_suppl.615S","article-title":"Ventilation\/perfusion ratios in pulmonary arterial hypertension: effects of IV and inhaled prostacyclin derivatives","volume":"128","author":"Bratel","year":"2005","journal-title":"Chest"},{"issue":"11","key":"10.1002\/14651858.CD003562.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1445-5994.2005.00934.x","article-title":"Combining treprostinil and sildenafil in the treatment of pulmonary hypertension","volume":"35","author":"Chua","year":"2005","journal-title":"Internal Medicine Journal"},{"key":"10.1002\/14651858.CD003562.pub2-BIB0034|cit34","unstructured":"Coyne TC Garces PC Kramer W No clinical interaction between sitaxsentan and sildenafil American Thoracic Society 2005 International Conference; May 20-25; San Diego, California 2005 A57; Poster: K70"},{"key":"10.1002\/14651858.CD003562.pub2-BIB0035|cit35","unstructured":"Gali\u00e8 N Burgess G Parpia T Barst R Effects of sildenafil on 1 year survival of patients with idiopathic pulmonary arterial hypertension (PAH) American Thoracic Society 2005 International Conference; May 20-25; San Diego, California 2005 C88"},{"issue":"20","key":"10.1002\/14651858.CD003562.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD003562.pub2-BIB0037|cit37","first-page":"1092","article-title":"The authors reply","volume":"354","author":"Gali\u00e8","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003562.pub2-BIB0038|cit38","first-page":"433","article-title":"Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies","volume":"90","author":"Gordeuk","year":"2005","journal-title":"Haematologica"},{"issue":"10","key":"10.1002\/14651858.CD003562.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ncpcardio0675","article-title":"Is sitaxsentan a safe and efficacious treatment for pulmonary arterial hypertension?","volume":"3","author":"Hoeper","year":"2006","journal-title":"Nature Clinical Practice Cardiovascular Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003562.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1253\/circj.69.461","article-title":"Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol","volume":"69","author":"Kataoka","year":"2005","journal-title":"Circulation Journal"},{"issue":"7","key":"10.1002\/14651858.CD003562.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.cardfail.2006.05.004","article-title":"Nesiritide acutely increases pulmonary and systemic levels of nitric oxide in patients with pulmonary hypertension","volume":"12","author":"Khush","year":"2006","journal-title":"Journal of Cardiac Failure"},{"key":"10.1002\/14651858.CD003562.pub2-BIB0042|cit42","unstructured":"Pepke-Zaba J Brown MCJ Parpia T Gilbert C Burgess G The impact of sildenafil citrate on health-related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double-blind, placebo controlled trial American Thoracic Society 2005 International Conference; May 20-25; San Diego, California 2005 B16"},{"issue":"12","key":"10.1002\/14651858.CD003562.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.rmed.2005.03.026","article-title":"Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension","volume":"99","author":"Preston","year":"2005","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD003562.pub2-BIB0044|cit44","unstructured":"Rubin L Burgess G Parpia T Simoneau G Effects of sildenafil on 6 minute walk distance (6MWD) and WHO functional class (FC) after 1 year of treatment American Thoracic Society 2005 International Conference; May 20-25; San Diego, California 2005 B16"},{"issue":"4","key":"10.1002\/14651858.CD003562.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"851 (e1-5)","DOI":"10.1016\/j.ahj.2005.09.006","article-title":"A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.","volume":"151","author":"Singh","year":"2006","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD003562.pub2-BIB0046|cit46","first-page":"52","article-title":"Tadalafil in the management of severe pulmonary artery hypertension","volume":"58","author":"Singh","year":"2006","journal-title":"Indian Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD003562.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/thx.2006.064097","article-title":"Long term imatinib treatment in pulmonary arterial hypertension","volume":"61","author":"Souza","year":"2006","journal-title":"Thorax"},{"issue":"3","key":"10.1002\/14651858.CD003562.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: A prospective, multicenter, open-label, 12-week trial","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD003562.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1136\/heart.84.2.e4","article-title":"Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension","volume":"84","author":"Abrams","year":"2000","journal-title":"Heart (Online)"},{"key":"10.1002\/14651858.CD003562.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin","volume":"121","author":"Barst","year":"1994","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD003562.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1097\/00000542-200006000-00044","article-title":"Sildenafil can increase the response to inhaled nitric oxide","volume":"92","author":"Bigatello","year":"2000","journal-title":"Anesthesiology"},{"key":"10.1002\/14651858.CD003562.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1164\/ajrccm.163.2.ed2000e","article-title":"Viagra for impotence of pulmonary vasodilator therapy?","volume":"163","author":"Lodato","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003562.pub2-BIB0053|cit53","article-title":"Prostacyclin for pulmonary hypertension (Cochrane review)","author":"Paramothayan","year":"2004","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"18","key":"10.1002\/14651858.CD003562.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM200011023431814","article-title":"Sildenafil in primary pulmonary hypertension (letter)","volume":"343","author":"Prasad","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"1 (Suppl 1)","key":"10.1002\/14651858.CD003562.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-9149(03)00824-5","article-title":"Overview of phosphodiesterase 5 inhibition in erectile dysfunction","volume":"92","author":"Rosen","year":"2003","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD003562.pub2-BIB0056|cit56","unstructured":"World Health Organisation Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998, Evian, France, 6-10 September 1998 http\/\/:www.who.int"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD003562.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T09:02:12Z","timestamp":1680944532000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003562.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2004,10,18]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003562.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,18]]}}}